GHK-Cu

GHK-Cu drops sharply with age and does striking things to cells in a dish. Whether any of that survives contact with actual human skin is a separate, unresolved question.

PCAC decided something about BPC-157 in July 2026, and most of the peptide world still can't say what, or what it doesn't mean.

GHK-Cu has some of the cleanest cell-biology data in peptide science: gene remodelling, wound signalling, antioxidant activity. Whether any of that survives the jump from a dish to a human body is still an open question.

Every study on GHK-Cu's wound-healing chemistry stops at the fibroblast dish. What happens once a wound closes, in the weeks that actually build a scar, is a different, mostly untested question.

GHK-Cu has a plausible, multi-pathway mechanism for hair-follicle regeneration, but almost all the evidence is in vitro and animal-model work from the 1990s and 2000s. No human trial has tested it in hair, and the sole human RCT in skin found no effect.

BPC-157, TB-500, and GHK-Cu are sold as one interchangeable injury-recovery stack, but their human evidence ranges from a real Phase 2 trial to a molecular identity gap to a null placebo-controlled result. Each is graded on its own record, not the group's pitch.

GHK-Cu is a copper-carrying peptide your body makes to repair itself, and makes less of as you age. Here's the plain-English answer: what it could do for you, why the biology is exciting, how far the human proof goes — and where the injectable form sits in the FDA's next compounding review.

The federal compounding framework applies the same way in every state. The state pharmacy boards do not. The result is a real state-by-state patchwork that decides whether a telehealth prescription for a compounded peptide is actually fillable where you live.

The "announcement" was a Joe Rogan appearance, not a Federal Register notice. The wellness scene heard one thing. The actual signal was narrower, and the rulemaking that turns it into access is still more than a year away.

Two days at FDA's White Oak campus decided which of seven peptides US compounding pharmacies may eventually dispense by prescription. The recommendation is not an approval, the docket is not all the peptides, and the framing the forums used going in was mostly wrong.

Chronic, low-grade inflammation tracks with slower recovery, stiff joints, and how fast you age. Three peptides under FDA review — KPV, BPC-157, and GHK-Cu — each turn it down from a different direction. Here is what that could mean for you, and how far the human proof actually goes.

Collagen is the scaffolding under your skin, tendons, and joints — and three peptides now in front of the FDA each lean on how your body builds it. Here is what that could mean for repair and ageing, why the biology is genuinely exciting, and how far the human proof actually goes.

Copper is a metal your body repairs itself with — but too reactive to carry loose, so it travels clipped to a small peptide. That's a copper peptide, like GHK-Cu. Here's why the biology is exciting, how far the human proof goes, and where the injectable sits in the FDA's next compounding review.

BPC-157 and GHK-Cu both get sold as tissue-repair peptides, but they are tools for two different jobs — BPC-157 for deep tissue like tendon and gut, GHK-Cu for skin and surface. Here is what each could do for you, which goal each one fits, and how far the proof actually goes.